ACR 2023 Annual Meeting
Saturday, May 6 – Wednesday, May 10, 2023
Learning Objectives
After completing this activity, the participant should be better able to:
- Recognize key leadership and practice management skills to enhance the value-based care of radiology.
- Discuss health policy trends impacting the radiology healthcare field and how technology is creating new opportunities to analyze and share information.
- Identify the key legislative issues that affect the radiology profession.
- Outline critical regulatory information on procedures and guidelines to enhance the practice of radiology.
- Cite 2-3 examples of current innovative technologies to improve performance and quality.
Physician Accreditation Statement
The American College of Radiology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ACR 2023 Credit Designation
The American College of Radiology designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
In order to successfully complete the activity, participants must, complete an activity evaluation and claim credit commensurate with their participation in the activity. This can be done via ACR’s credit claiming site: https://www.highmarksce.com/acr/claimcredit , utilizing your username and password. An e-mail from mgrant@acr.org will be sent with access to the site, along with instructions.
Contact Information
For information about the accreditation of this program, please contact the ACR at mgrant@acr.org or carmstrong@acr.org.
Disclosure of Relevant Financial Relationships
The American College of Radiology (ACR) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by ACR are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by ACR in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by ACR to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by the ACR.
The following planners and managers have no relevant financial relationships with ineligible companies:
- Alison Loughlin
- Mark Alson, MD, FACR
- Johnson Benjamin Lightfoote, MD
- James Borgstede, MD
- Lori Deitte, MD
- Eric Rubin, MD
- Frank Lexa, MD, MBA, FACR
- Ryan K. Lee, MD, MBA
- Laura A. Vallow, MD
- Gregory N. Nicola, MD, FACR
- Maya Grant
- Theresa Rudolph
- Carlye Armstrong, CHCP
The following planners and managers have the following relevant financial relationships with ineligible companies:
| Catherine J. Everett, MD, MBA, FACR | Stock Shareholder: Dicom Director |
| Rajan T. Gupta, MD | Consulting Fee: Bayer Pharma AG, Bard, Quibim, Philips, Bracco Diagnostics; Speakers’ Bureau: Bayer Pharma AG |
| Albert Attia, MD | Consulting Fee: Novocure |
The following faculty members have no relevant financial relationships with ineligible companies:
- Frank J. Lexa, MD, MBA, FACR
- Ryan K. Lee, MD, MBA
- Jacqueline Anne Bello, MD, FACR
- Lauren Nicola, MD
- Gregory N. Nicola, MD, FACR
- Richard Duszak, MD, FACR, FSIR, FRBMA
- James P. Borgstede, MD, FACR
- Eric Rubin, MD, FACR
- Melissa A. Davis, MD, MBA
- Aaron Bush, MD
- Kurt Schoppe, MD
- Andrew Moriarity, MD
- Michael Booker, MD
- Dana Smetherman, MD
- Melissa Chen, MD
- Richard Heller, MD
- Keith J. Dreyer
The following faculty members (speakers and content developers) have the following relevant financial relationships with ineligible companies:
| Michele H. Johnson, MD, FACR | Consulting Fee: IschemaView, Inc. |
| Geoffrey D. Rubin, MD, MBA, FACR | Consulting Fee: Nanox, Fovia; Stock Shareholder: Heartflow |
| William Small, Jr., MD, FACRO, FACR, FASTRO | Consulting Fee: Novocure Honoraria: Zeiss |
| Taj Kattapuram, MD | Consulting Fee: Sauzio, Inc., Vituity, Inc., Carpe AI |
| Tessa S. Cook MD, PhD, CIIP, FSIIM | Honoraria: Sectra |
| Amy Patel, MD | Consulting Fee: Hologic; Stock Shareholder: Kheiron Medical |
| Join Y. Luh, MD, FACR | Consulting Fee: MVision AI |
| Arya Amini, MD | Consulting Fee: AstraZeneca; Contracted Research: Genentech, Varian, RefleXion; Speakers' Bureau: AstraZeneca, Takeda Pharmaceutical |
| Sammy Chu, MD | Stock Shareholder: Johnson & Johnson, Thermo Fisher Scientific, Inc., Stryker Corporation, Guardant Health, Inc., Cardinal Health, Inc. |
The following content reviewers have no relevant financial relationships with ineligible companies:
- Tanvir Rizvi, MD